Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

67%

6 of 9 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

3(33.3%)

Phase 3

1(11.1%)

9Total

Phase 1(5)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04066023Phase 2Completed

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

Role: lead

NCT03978403Phase 1Completed

A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers

Role: lead

NCT04969497Phase 1Completed

Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

Role: lead

NCT03282227Phase 3Completed

A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

Role: lead

NCT03708744Phase 1Completed

A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers

Role: lead

NCT00489918Phase 2Completed

Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis

Role: lead

NCT02745392Phase 2Completed

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

Role: lead

NCT02478879Phase 1Completed

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

Role: lead

NCT02459938Phase 1Completed

Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia

Role: lead

All 9 trials loaded